Previous close | 89.25 |
Open | 90.65 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 90.15 - 90.65 |
52-week range | 72.98 - 93.58 |
Volume | |
Avg. volume | 179,009 |
Market cap | 192.367B |
Beta (5Y monthly) | 0.46 |
PE ratio (TTM) | 28.44 |
EPS (TTM) | 3.17 |
Earnings date | N/A |
Forward dividend & yield | 3.43 (3.80%) |
Ex-dividend date | 09 Mar 2023 |
1y target est | N/A |
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
The stock market is in a precarious place. The sharp rise in both interest rates and bond yields has weighed heavily on most stocks since the first quarter of 2022. The top-shelf drugmakers Novartis (NYSE: NVS) and Vertex Pharmaceuticals (NASDAQ: VRTX) are two prime examples.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.